Uveal melanoma is very rare, with an annual incidence of about 5 to 6 per million people and requires specialized advanced treatment. Northwestern Medicine is one of the few institutions in the U.S. offering both proton beam therapy and plaque brachytherapy for uveal melanoma.
Here, Chris Bowen, MD, an ophthalmic oncologist and retina surgeon at Northwestern Medicine, discusses these treatment modalities, offered by his multidisciplinary team, that allow for personalized care and improved outcomes.
[ Ссылка ]
